전형적인 지속성 발작을 보이는 12세 이상의 연구 참여자를 대상으로 스타카토 알프라졸람의 효능 및 안전성을 테스트하기 위한 연구
전형적으로 지속되는 발작이 있는 12세 이상의 연구 참여자에서 스타카토 알프라졸람의 효능과 안전성을 평가하기 위한 이중 맹검, 무작위, 위약 대조, 다기관, 외래 환자, 병렬 그룹 연구
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: UCB Cares
- 전화번호: 0018445992273
- 이메일: UCBCares@ucb.com
연구 연락처 백업
- 이름: UCB Cares
- 전화번호: 1-844-599-2273 (USA)
- 이메일: UCBCares@ucb.com
연구 장소
-
-
-
Aachen, 독일
- 빼는
- Ep0162 40577
-
Berlin, 독일
- 모병
- Ep0162 40683
-
Bielefeld, 독일
- 모병
- Ep0162 40685
-
Erlangen, 독일
- 모병
- Ep0162 40023
-
Frankfurt am Main, 독일
- 모병
- Ep0162 40645
-
Kehl-kork, 독일
- 완전한
- Ep0162 40689
-
Marburg, 독일
- 모병
- Ep0162 40529
-
München, 독일
- 빼는
- Ep0162 40724
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85004
- 모병
- Ep0162 50506
-
Scottsdale, Arizona, 미국, 85253
- 모병
- Ep0162 50720
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- 완전한
- Ep0162 50494
-
-
California
-
Downey, California, 미국, 90242
- 모병
- Ep0162 50118
-
La Jolla, California, 미국, 92037
- 모병
- Ep0162 50416
-
Long Beach, California, 미국, 90806
- 모병
- Ep0162 50702
-
Los Angeles, California, 미국, 90095
- 빼는
- Ep0162 50505
-
Orange, California, 미국, 92868
- 완전한
- Ep0162 50492
-
Poway, California, 미국, 92064
- 빼는
- Ep0162 50722
-
Sacramento, California, 미국, 95817
- 모병
- Ep0162 50716
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06519
- 완전한
- Ep0162 50367
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20037
- 모병
- Ep0162 50088
-
-
Florida
-
Boca Raton, Florida, 미국, 33486
- 빼는
- Ep0162 50721
-
Gulf Breeze, Florida, 미국, 32561
- 완전한
- Ep0162 50515
-
Jacksonville, Florida, 미국, 32224-1865
- 모병
- Ep0162 50342
-
Jacksonville, Florida, 미국, 32209-6533
- 모병
- Ep0162 50508
-
Miami, Florida, 미국, 33136
- 모병
- Ep0162 50199
-
Miami, Florida, 미국, 33176
- 모병
- Ep0162 50676
-
Orlando, Florida, 미국, 32806
- 완전한
- Ep0162 50509
-
Rockledge, Florida, 미국, 32955
- 모병
- Ep0162 50703
-
Tampa, Florida, 미국, 33606
- 모병
- Ep0162 50308
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96817
- 모병
- Ep0162 50323
-
-
Idaho
-
Boise, Idaho, 미국, 83702
- 모병
- Ep0162 50512
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Ep0162 50493
-
Springfield, Illinois, 미국, 62702
- 빼는
- Ep0162 50375
-
-
Indiana
-
Fort Wayne, Indiana, 미국, 46804
- 모병
- Ep0162 50504
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- 빼는
- Ep0162 50561
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70122
- 모병
- Ep0162 50517
-
New Orleans, Louisiana, 미국, 70121
- 빼는
- Ep0162 50395
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 빼는
- Ep0162 50093
-
Bethesda, Maryland, 미국, 20817
- 빼는
- Ep0162 50488
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02118
- 모병
- Ep0162 50615
-
Boston, Massachusetts, 미국, 02215
- 완전한
- Ep0162 50047
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 완전한
- Ep0162 50110
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- 모병
- Ep0162 50507
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89128
- 빼는
- Ep0162 50499
-
-
New Jersey
-
Neptune City, New Jersey, 미국, 07753
- 빼는
- Ep0162 50626
-
New Brunswick, New Jersey, 미국, 08901
- 모병
- Ep0162 50299
-
-
New York
-
Buffalo, New York, 미국, 14221
- 모병
- Ep0162 50497
-
New Hyde Park, New York, 미국, 11042
- 완전한
- Ep0162 50625
-
New York, New York, 미국, 10016
- 모병
- Ep0162 50298
-
New York, New York, 미국, 10029
- 모병
- Ep0162 50490
-
New York, New York, 미국, 10075
- 모병
- Ep0162 50518
-
Rochester, New York, 미국, 14642
- 모병
- Ep0162 50034
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204
- 모병
- Ep0162 50514
-
Charlotte, North Carolina, 미국, 28207
- 빼는
- Ep0162 50487
-
Durham, North Carolina, 미국, 27705
- 모병
- Ep0162 50715
-
-
Ohio
-
Akron, Ohio, 미국, 44308
- 빼는
- Ep0162 50371
-
Cleveland, Ohio, 미국, 44195
- 빼는
- Ep0162 50528
-
-
Oregon
-
Portland, Oregon, 미국, 97239-3098
- 빼는
- Ep0162 50510
-
Portland, Oregon, 미국, 97227
- 완전한
- Ep0162 50724
-
Portland, Oregon, 미국, 97239
- 모병
- Ep0162 50701
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Ep0162 50096
-
Philadelphia, Pennsylvania, 미국, 19107
- 모병
- Ep0162 50364
-
Philadelphia, Pennsylvania, 미국, 19140
- 모병
- Ep0162 50089
-
Pittsburgh, Pennsylvania, 미국, 15212
- 모병
- Ep0162 50511
-
Pittsburgh, Pennsylvania, 미국, 15213
- 모병
- Ep0162 50491
-
-
Tennessee
-
Chattanooga, Tennessee, 미국, 37403
- 모병
- Ep0162 50700
-
Memphis, Tennessee, 미국, 38103-2800
- 모병
- Ep0162 50513
-
Nashville, Tennessee, 미국, 37232
- 모병
- Ep0162 50103
-
-
Texas
-
Austin, Texas, 미국, 78749
- 모병
- Ep0162 50731
-
Houston, Texas, 미국, 77459
- 모병
- Ep0162 50525
-
Houston, Texas, 미국, 77030
- 모병
- Ep0162 50714
-
Round Rock, Texas, 미국, 78681
- 빼는
- Ep0162 50496
-
-
Utah
-
Salt Lake City, Utah, 미국, 84132
- 모병
- Ep0162 50473
-
-
Virginia
-
Winchester, Virginia, 미국, 22601
- 모병
- Ep0162 50726
-
-
-
-
-
Blagoevgrad, 불가리아
- 모병
- Ep0162 40650
-
Pazardzhik, 불가리아
- 모병
- Ep0162 40708
-
Pleven, 불가리아
- 완전한
- Ep0162 40665
-
Pleven, 불가리아
- 완전한
- Ep0162 40709
-
Sofia, 불가리아
- 완전한
- Ep0162 40651
-
-
-
-
-
Barcelona, 스페인
- 모병
- Ep0162 40160
-
L'Hospitalet de Llobregat, 스페인
- 모병
- Ep0162 40157
-
Madrid, 스페인
- 모병
- Ep0162 40540
-
Pamplona, 스페인
- 모병
- Ep0162 40352
-
Seville, 스페인
- 모병
- Ep0162 40668
-
Terrassa, 스페인
- 모병
- Ep0162 40453
-
Valencia, 스페인
- 모병
- Ep0162 40230
-
Valladolid, 스페인
- 완전한
- Ep0162 40667
-
-
-
-
-
Birmingham, 영국
- 모병
- Ep0162 40686
-
Cardiff, 영국
- 빼는
- Ep0162 40300
-
Glasgow, 영국
- 모병
- Ep0162 40735
-
London, 영국
- 모병
- Ep0162 40833
-
Oxford, 영국
- 모병
- Ep0162 40163
-
Salford, 영국
- 모병
- Ep0162 40108
-
-
-
-
-
Catanzaro, 이탈리아
- 빼는
- Ep0162 40690
-
Genova, 이탈리아
- 모병
- Ep0162 40674
-
Milan, 이탈리아
- 모병
- Ep0162 40144
-
Pavia, 이탈리아
- 모병
- Ep0162 40477
-
Roma, 이탈리아
- 모병
- Ep0162 40257
-
Roma, 이탈리아
- 완전한
- Ep0162 40675
-
-
-
-
-
Fukuoka, 일본
- 모병
- Ep0162 20248
-
Hachioji-shi, 일본
- 모병
- Ep0162 20070
-
Hamamatsu, 일본
- 빼는
- Ep0162 20237
-
Hiroshima, 일본
- 모병
- Ep0162 20249
-
Hōfu, 일본
- 모병
- Ep0162 20236
-
Itami, 일본
- 모병
- Ep0162 20239
-
Kodaira, 일본
- 모병
- Ep0162 20143
-
Koshi-shi, 일본
- 모병
- Ep0162 20315
-
Kyoto, 일본
- 모병
- Ep0162 20147
-
Nagakute, 일본
- 완전한
- Ep0162 20243
-
Nagoya, 일본
- 모병
- Ep0162 20235
-
Niigata, 일본
- 모병
- Ep0162 20238
-
Osaka, 일본
- 모병
- Ep0162 20302
-
Sapporo, 일본
- 모병
- Ep0162 20316
-
Shimotsuga-gun, 일본
- 모병
- Ep0162 20337
-
Shinjuku-ku, 일본
- 모병
- Ep0162 20297
-
Shizuoka, 일본
- 모병
- Ep0162 20240
-
Suita, 일본
- 모병
- Ep0162 20242
-
Tōon, 일본
- 모병
- Ep0162 20266
-
Yamagata, 일본
- 모병
- Ep0162 20244
-
Ōmura, 일본
- 모병
- Ep0162 20241
-
-
-
-
-
Beijing, 중국
- 모병
- Ep0162 20246
-
Beijing, 중국
- 모병
- Ep0162 20299
-
Beijing, 중국
- 빼는
- Ep0162 20128
-
Beijing, 중국
- 완전한
- Ep0162 20268
-
Changchun, 중국
- 모병
- Ep0162 20261
-
Chengdu, 중국
- 모병
- Ep0162 20133
-
Chengdu, 중국
- 모병
- Ep0162 20137
-
Chongqing, 중국
- 빼는
- Ep0162 20250
-
Chongqing, 중국
- 모병
- Ep0162 20334
-
Fuzhou, 중국
- 모병
- Ep0162 20179
-
Guangzhou, 중국
- 모병
- Ep0162 20269
-
Guangzhou, 중국
- 모병
- Ep0162 20300
-
Guangzhou, 중국
- 모병
- Ep0162 20124
-
Guangzhou, 중국
- 완전한
- Ep0162 20260
-
Guangzhou, 중국
- 완전한
- Ep0162 20264
-
Hangzhou, 중국
- 모병
- Ep0162 20022
-
Kunming, 중국
- 모병
- Ep0162 20320
-
Lanzhou, 중국
- 모병
- Ep0162 20258
-
Nanchang, 중국
- 빼는
- Ep0162 20253
-
Nanjing, 중국
- 모병
- Ep0162 20267
-
Nanning, 중국
- 모병
- Ep0162 20331
-
Qingdao, 중국
- 모병
- Ep0162 20333
-
Shanghai, 중국
- 빼는
- Ep0162 20123
-
Shanghai, 중국
- 모병
- Ep0162 20292
-
Shenzhen, 중국
- 빼는
- Ep0162 20332
-
Shijiazhuang, 중국
- 모병
- Ep0162 20289
-
Suzhou, 중국
- 모병
- Ep0162 20119
-
Tianjin, 중국
- 모병
- Ep0162 20257
-
Wenzhou, 중국
- 모병
- Ep0162 20025
-
Wuhan, 중국
- 빼는
- Ep0162 20252
-
Yinchuan, 중국
- 빼는
- Ep0162 20255
-
Zhanjiang, 중국
- 모병
- Ep0162 20262
-
Zhengzhou, 중국
- 모병
- Ep0162 20251
-
-
-
-
-
Brno, 체코
- 모병
- Ep0162 40670
-
Ostrava - Poruba, 체코
- 모병
- Ep0162 40672
-
Prague, 체코
- 모병
- Ep0162 40671
-
Prague, 체코
- 모병
- Ep0162 40714
-
Prague, 체코
- 완전한
- Ep0162 40063
-
-
-
-
-
Bydgoszcz, 폴란드
- 모병
- Ep0162 40707
-
Gdansk, 폴란드
- 모병
- Ep0162 40677
-
Krakow, 폴란드
- 빼는
- Ep0162 40219
-
Krakow, 폴란드
- 모병
- Ep0162 40842
-
Krakow, 폴란드
- 완전한
- Ep0162 40502
-
Lublin, 폴란드
- 완전한
- Ep0162 40676
-
Nowa Sól, 폴란드
- 모병
- Ep0162 40091
-
Poznan, 폴란드
- 빼는
- Ep0162 40153
-
Świdnik, 폴란드
- 완전한
- Ep0162 40678
-
-
-
-
-
Bron, 프랑스
- 모병
- Ep0162 40681
-
Bron, 프랑스
- 빼는
- Ep0162 40688
-
Dijon, 프랑스
- 빼는
- Ep0162 40680
-
Marseille, 프랑스
- 빼는
- Ep0162 40130
-
Paris, 프랑스
- 모병
- Ep0162 40682
-
Paris, 프랑스
- 빼는
- Ep0162 40019
-
Rennes, 프랑스
- 모병
- Ep0162 40201
-
Strasbourg, 프랑스
- 모병
- Ep0162 40199
-
-
-
-
-
Balassagyarmat, 헝가리
- 모병
- Ep0162 40666
-
Budapest, 헝가리
- 모병
- Ep0162 40673
-
Budapest, 헝가리
- 모병
- Ep0162 40704
-
Debrecen, 헝가리
- 모병
- Ep0162 40653
-
-
-
-
-
Fitzroy, 호주
- 모병
- Ep0162 30016
-
Herston, 호주
- 모병
- Ep0162 30030
-
Melbourne, 호주
- 빼는
- Ep0162 30027
-
South Brisbane, 호주
- 모집하지 않고 적극적으로
- Ep0162 30031
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Participant must be ≥12 years of age at the Baseline/Randomization Visit
-
Participant must have a study caregiver ≥18 years of age at the Screening Visit; the study caregiver(s) must be a relative, partner, friend, or legally authorized representative (LAR) of the participant, or a person who provides daily care to the participant and has a significant personal relationship with the participant; the study caregiver(s) must be able to recognize and observe the participant's seizures
-
Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:
- Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes
- Episodes of a focal seizure with a minimum duration of 3 minutes
- Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes
-
Prior to the Screening Visit, participant has experienced ≥4 stereotypical episodes of prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of prolonged seizures must have occurred within the 3 months prior to the Screening Visit
-
Participant has had a documented brain computerized tomography or magnetic resonance imaging review, performed after diagnosis of epilepsy and within the 5 years prior to the Screening Visit, that confirms the absence of a progressive neurological disorder
-
Participant is receiving a regimen of antiseizure medications (ASMs) that has been stable (ie, no addition or removal of ASM[s]; dose adjustments are permitted to ASM[s]; dose adjustments are not permitted for benzodiazepines) for 30 days prior to the Screening Visit
-
Male and female participants:
- A male participant must agree to use contraception during the Outpatient Treatment Period and for at least 7 days after IMP administration and refrain from donating sperm during this period
- A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the Outpatient Treatment Period and for at least 30 days after IMP administration
-
Participant is capable of giving signed informed consent (or giving assent, where required), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), the protocol, and the individualized participant management plan (iPMP). The ICF or a specific assent form, where required, will be signed and dated by minors
-
The participant's study caregiver(s) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF, the protocol, and the iPMP
Exclusion Criteria:
- Participant has a current history of alcohol or drug use disorder, as defined in the Diagnostic and Statistical Manual of Mental Disorders 5, within the previous 1 year
- Participant has a known hypersensitivity to any components of the IMP or comparable drugs (and/or an investigational device) as stated in this protocol or to albuterol (or similar bronchospasm rescue medication if needed to meet country-specific requirements)
- Participant has a diagnosis of atrial fibrillation or mitral stenosis
- Participant has a history of convulsive (generalized tonic-clonic) status epilepticus in the 8 weeks prior to the Screening Visit
- Participant has a history or presence of known nonepileptic seizures which cannot be distinguished from qualifying epileptic seizures
- Participant has a clinically significant known airway hypersensitivity (eg, bronchospasm to known allergens, such as pollen, animals, or food) and/or acute respiratory signs/symptoms (eg, shortness of breath, wheezing on lung auscultation)
- Participant has a clinically significant chronic pulmonary disorder other than mild asthma (eg, chronic obstructive pulmonary disease, restrictive lung diseases [including idiopathic pulmonary fibrosis]) and/or recent history or presence of hemoptysis or pneumothorax
- Participant has had a positive antigen test for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced moderate to severe signs/symptoms of respiratory distress necessitating hospitalization or outpatient treatment such as ambulatory oxygen, extensive treatment with inhaler medications, and/or oral medications for a duration of 4 weeks or more, unless full resolution occurred at least 6 months prior to Screening
- Participant has experienced a upper respiratory tract infection within 4 weeks or bronchitis/pneumonia within 3 months before the Screening Visit
- Participant has a history or presence of acute narrow-angle glaucoma
- Participant has a condition for which oral alprazolam is contraindicated (eg, myasthenia gravis, severe respiratory insufficiency, and sleep apnea syndrome)
- Participant has a history or presence of long QT syndrome, a family history of sudden death due to long QT syndrome, or unexplained syncope
- Chronic use of benzodiazepines for more than 3 days within a period of 7 days will be allowed for approximately 30 % of study participants
- Participant is taking any drug that is a strong CYP3A4 inhibitor, including azole antifungal agents (ketoconazole and itraconazole) and nefazodone
- Participant is taking any opioids (eg, fentanyl, oxycodone, morphine) or sedative hypnotics on a chronic basis
- Participant is taking nonselective beta blockers on a chronic basis
- Participant is taking pharmacotherapy for an active major psychiatric disorder where major changes in regimen are needed or anticipated during the study
- Participant has been treated with vagal nerve stimulation (VNS) for less than 6 months or VNS settings have changed within 30 days before the Screening Visit
- Participant has a clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator
- Participant has an oxygen saturation <95 % (or less than normal in regions of altitude >2500 meters) for greater than 30 seconds during the Screening Visit. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
- Participant has >2.0x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome or >2.0xULN total bilirubin for liver impairment)
- Participant has current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis
- Participant has a QT interval corrected for heart rate (QTc) >450 msec (males), QTc interval >470 msec (females), or QTc interval >480 msec (participants with bundle branch block), PR interval ≥220 msec, or any other clinically significant electrocardiogram (ECG) abnormality according to the Investigator i) The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF). It is either machine-read or manually over-read
- Participant has a positive urine screen for drugs of abuse at the Screening Visit
- Participant has a blood pressure (BP) or heart rate (HR) outside the following range after 5 minutes rest: systolic BP: 90 mmHg to 150 mmHg; diastolic BP: 4 0mmHg to 95 mmHg; HR: 50 bpm to 100 bpm. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Staccato alprazolam Arm
Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation. |
Route of administration: Inhalation Participants will receive one dose of Staccato alprazolam during the Treatment Period.
다른 이름들:
|
|
위약 비교기: Placebo Arm
Participants randomized to this arm will receive a single dose of placebo by inhalation. |
Route of administration: Inhalation Participants will receive one dose of placebo during the Treatment Period. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment success for the treated seizure within 90 seconds after investigational medicinal product (IMP) administration
기간: From start of IMP treatment through 6 hours
|
Treatment success for the treated seizure is defined as termination of the seizure within 90 seconds after IMP administration. |
From start of IMP treatment through 6 hours
|
|
Treatment success for the treated seizure with no recurrence up to 2 hours
기간: From start of IMP treatment through 2 hours
|
Treatment success for the treated seizure is defined as termination of the treated seizure within 90 seconds after IMP administration and no recurrence of seizure(s) from IMP administration to 2 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 2 hours after IMP administration. |
From start of IMP treatment through 2 hours
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment success for treated seizure with no recurrence after 4 hours
기간: From start of IMP treatment through 4 hours
|
Treatment success defined as termination of the treated seizure within 90 seconds after IMP administration, with no recurrence of seizure(s) up to 4 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 4 hours after IMP administration. |
From start of IMP treatment through 4 hours
|
|
Treatment success for treated seizure with no recurrence after 6 hours
기간: From start of IMP treatment through 6 hours
|
Treatment success defined as termination of the treated seizure within 90 seconds after IMP administration, with no recurrence of seizure(s) up to 6 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 6 hours after IMP administration. |
From start of IMP treatment through 6 hours
|
|
Time from IMP administration to cessation of the treated seizure
기간: From start of IMP treatment through 6 hours
|
The time will be assessed from IMP administration to cessation of the treated seizure (taking administration of seizure rescue treatment as censoring point). |
From start of IMP treatment through 6 hours
|
|
Frequency of respiratory treatment emergent adverse events (TEAEs)
기간: From start of IMP treatment up to the Safety Follow-up Visit (Week 19)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. |
From start of IMP treatment up to the Safety Follow-up Visit (Week 19)
|
|
Number of subsequent seizure(s) up to 2 hours after IMP administration
기간: From start of IMP treatment through 2 hours
|
The number of subsequent seizure(s) will be assessed up to 2 hours after IMP administration. |
From start of IMP treatment through 2 hours
|
|
Time to first subsequent seizure up to 2 hours after IMP administration
기간: From start of IMP treatment through 2 hours
|
The time to first subsequent seizure will be assessed up to 2 hours after IMP administration and is defined as time from end of IMP treated seizure to start of first subsequent seizure. |
From start of IMP treatment through 2 hours
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: UCB Cares, 001 844 599 2273 (UCB)
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- EP0162
- 2021-002686-18 (EudraCT 번호)
- U1111-1303-2588 (기타 식별자: Universal Trial Number (UTN))
- 2024-510950-29 (레지스트리 식별자: EU CT Number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of reidentifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD 공유 기간
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD 공유 액세스 기준
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .